about
Genome-wide association studies identify four ER negative-specific breast cancer risk lociCellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyTargeted Therapies in Triple-Negative Breast CancerPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trialLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocolIntensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.Acceptance of oral chemotherapy in breast cancer patients - a survey study.Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Targeted Therapy in Breast Cancer.Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).Carcinoma of Unknown Primary - an Orphan Disease?
P50
Q24622610-20492512-AB85-49E6-9FE3-99F49C9536CAQ26745444-6BA39910-AA23-45B7-B255-6C044610DC89Q26777736-D79409C4-933B-49E9-862E-BD4FAA6462B5Q27853134-BA9A50D2-88D0-4DF9-8881-602B8D5BB377Q28237833-90C7A3A7-41AB-45FA-9923-DF82F5C09BB3Q28291395-C7E323B6-9180-4517-BF2E-CAA9FB08670DQ28389045-B2C0DCAB-8DE0-4489-915C-EF027CE7DBFEQ29416989-CB5811CD-7425-4546-88F1-C68461B4E395Q30313214-BC451E41-3579-4485-B81D-5E644EA32DDAQ30315970-D76532B3-5EF4-49EC-B99C-A2ECC80EB762Q30316383-D1BFB06A-8613-4C42-B80E-72AB78BC2CEFQ30317450-C9AFCDBB-E0D9-4083-BD30-A3F16D1B65E7Q30317570-5563D121-D176-4965-8453-E615C431F6B9Q30317734-F73B9B29-2CB9-488A-A222-17D616BA96FBQ30374367-432F4668-28CD-4AD1-A4A3-FDB1B7214764Q30588206-EFF88F3C-CCAF-4A0C-BD87-23F34EE8DB2FQ30976616-5ED041F7-81A4-4733-835A-D77F5167EC5FQ31082788-611B54A4-63F9-4586-9AFB-A774BE4AE567Q31107007-743A019E-F021-4186-85A6-F8417838F8A1Q31141769-C3DCA324-A278-4C9C-A537-169A20448951Q31153453-93A08DD4-4C41-4569-9C4F-6F597BBD7221Q33311401-8072B989-7B4E-49F3-9B2C-E08F4F9041BAQ33384086-F0AC8809-A22F-4B10-BD49-1AF3B820CE32Q33385484-0203E9A9-0837-4C77-8CC5-3D6086A558EFQ33391647-FE3C82A2-C32E-4DBF-81FA-F7FA7893A66DQ33411565-ADC8C595-943E-49F8-9BC7-269DBCBEB6F1Q33415041-1FD536DB-B287-4A87-B33C-66AEBF1BBEECQ33421285-DB26018F-3AE2-4237-99AA-95B5DC68037FQ33425044-D473711E-073F-4B2B-8E9A-52298E389F90Q33432594-3D0C3A18-085E-4C4B-AD07-98A5A3C0C555Q33574416-9570EAC7-B85D-4FED-A3D8-84FFE8FAF5E6Q33769034-0304CF3C-05A9-4DC9-B245-9793B64CD9A0Q33806358-DDC4A0A9-9BE1-4812-B9B8-6A1CB171DEC0Q33870472-ED59FD31-7E5C-4EEC-A77B-8CC033A9DD06Q33958981-C7D4957F-82A7-424B-8F42-7CFC634A0AAAQ34022546-E969CF9F-37A8-48E8-A8C8-D4A345F6E73FQ34052424-BD842D9C-097D-41E2-9A46-23B3BF8D95ABQ34096056-C0BD2AD9-5B67-4E32-BE8E-22E593C40955Q34096155-AE1B55C5-E0CE-4552-8233-C5B7E0593AB0Q34096326-CE1477D4-7F1B-479C-A417-5F82E6E215C6
P50
description
onderzoeker
@nl
name
Andreas Schneeweiss
@ast
Andreas Schneeweiss
@en
Andreas Schneeweiss
@es
Andreas Schneeweiss
@nl
Andreas Schneeweiss
@sl
type
label
Andreas Schneeweiss
@ast
Andreas Schneeweiss
@en
Andreas Schneeweiss
@es
Andreas Schneeweiss
@nl
Andreas Schneeweiss
@sl
prefLabel
Andreas Schneeweiss
@ast
Andreas Schneeweiss
@en
Andreas Schneeweiss
@es
Andreas Schneeweiss
@nl
Andreas Schneeweiss
@sl
P214
P106
P21
P214
P31
P735
P7859
viaf-62134139